Invega Trinza, Pentasa, and Abilify LAI Top Viatris’ First Complex Ambitions

Viatris spent a good chunk of its recent investor day updating on its complex generics ambitions, especially considering it is set to be missing biosimilars from its armory in the back half of 2022. A proposed move for the first US generic Symbicort was suggested by management.